Scholarlink

Background <p>Limited real-world data on biological drug use in older patients with immune-mediated inflammatory diseases (IMIDs) exist despite these drugs carrying serious risks in this population.</p> Objective <p>We aimed to describe the frequency and persistence of biological drug use in older patients (≥ 65&#xa0;years) with IMID, including inflammatory bowel diseases (IBDs), psoriatic arthritis/psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis, in a large Italian population.</p> Methods <p>A retrospective cohort study using the VALORE distributed claims database network from 13 Italian regions in the years 2010–2022 was performed. Older patients with IMID receiving biological drugs were included. Yearly prevalence of biological drug use and treatment persistence among incident users, from first dispensing to discontinuation/switching to another drug, was measured. Multivariable logistic regression was employed to identify treatment discontinuation predictors.</p> Results <p>The prevalence of biological drug use in older patients with IMID increased dramatically from 2010 (0.44 per 1000 residents) to 2022 (2.48 per 1000 residents). Overall, 25,284 incident users of biological drugs were identified, with a female/male ratio of 1.6 and a mean age of 71.0 (standard deviation ± 5.2) years. The median duration of follow-up was 4.2 (2.5–6.6) years, and the most common indication for use was RA (<i>n</i> = 8371; 33.1%). Overall, biological drug persistence was 54.4% at 1 year from treatment start. The highest persistence rates were found for vedolizumab and ustekinumab in patients with IBD (ulcerative colitis, 68.1% and 76.2%, respectively; Crohn’s disease, 69.6% and 88.1%, respectively). Polypharmacy, advanced age, and female sex were identified as predictors of treatment discontinuation.</p> Conclusions <p>This study documented a significant rise in biological drug use among older patients with IMID in Italy over the last decade. Around 50% of users discontinued treatment after the first year, with even higher rates observed in very old patients with polypharmacy. These findings highlight potential concerns about the use of biological therapies in older patients and underscore the urgent need for large-scale cohort studies to address the current knowledge gaps regarding their safety and effectiveness in this vulnerable population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Frequency of Biological Drug Use in Older Patients with Immune-Mediated Inflammatory Diseases: Results from the Large-Scale Italian VALORE Distributed Database Network

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月3日

查看全文
  • Federica Soardo,
  • Andrea Spini,
  • Giorgia Pellegrini,
  • Giorgio Costa,
  • Clément Mathieu,
  • Chiara Bellitto,
  • Luca L’Abbate,
  • Ylenia Ingrasciotta,
  • Olivia Leoni,
  • Martina Zanforlini,
  • Domenica Ancona,
  • Paolo Stella,
  • Anna Cavazzana,
  • Angela Scapin,
  • Sara Lopes,
  • Valeria Belleudi,
  • Stefano Ledda,
  • Paolo Carta,
  • Paola Rossi,
  • Lucian Ejlli,
  • Ester Sapigni,
  • Aurora Puccini,
  • Rita Francesca Scarpelli,
  • Giovambattista De Sarro,
  • Alessandra Allotta,
  • Sebastiano Addario Pollina,
  • Roberto Da Cas,
  • Giampaolo Bucaneve,
  • Antea Maria Pia Mangano,
  • Francesco Balducci,
  • Carla Sorrentino,
  • Ilenia Senesi,
  • Marco Tuccori,
  • Rosa Gini,
  • Stefania Spila-Alegiani,
  • Marco Massari,
  • Silvana Anna Maria Urru,
  • Annalisa Campomori,
  • Gianluca Trifirò

摘要

Background

Limited real-world data on biological drug use in older patients with immune-mediated inflammatory diseases (IMIDs) exist despite these drugs carrying serious risks in this population.

Objective

We aimed to describe the frequency and persistence of biological drug use in older patients (≥ 65 years) with IMID, including inflammatory bowel diseases (IBDs), psoriatic arthritis/psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis, in a large Italian population.

Methods

A retrospective cohort study using the VALORE distributed claims database network from 13 Italian regions in the years 2010–2022 was performed. Older patients with IMID receiving biological drugs were included. Yearly prevalence of biological drug use and treatment persistence among incident users, from first dispensing to discontinuation/switching to another drug, was measured. Multivariable logistic regression was employed to identify treatment discontinuation predictors.

Results

The prevalence of biological drug use in older patients with IMID increased dramatically from 2010 (0.44 per 1000 residents) to 2022 (2.48 per 1000 residents). Overall, 25,284 incident users of biological drugs were identified, with a female/male ratio of 1.6 and a mean age of 71.0 (standard deviation ± 5.2) years. The median duration of follow-up was 4.2 (2.5–6.6) years, and the most common indication for use was RA (n = 8371; 33.1%). Overall, biological drug persistence was 54.4% at 1 year from treatment start. The highest persistence rates were found for vedolizumab and ustekinumab in patients with IBD (ulcerative colitis, 68.1% and 76.2%, respectively; Crohn’s disease, 69.6% and 88.1%, respectively). Polypharmacy, advanced age, and female sex were identified as predictors of treatment discontinuation.

Conclusions

This study documented a significant rise in biological drug use among older patients with IMID in Italy over the last decade. Around 50% of users discontinued treatment after the first year, with even higher rates observed in very old patients with polypharmacy. These findings highlight potential concerns about the use of biological therapies in older patients and underscore the urgent need for large-scale cohort studies to address the current knowledge gaps regarding their safety and effectiveness in this vulnerable population.